Fierce Healthcare
NOVEMBER 20, 2022
Walgreens plots 'aggressive' strategy to build out healthcare services, CEO Roz Brewer says. hlandi. Sun, 11/20/2022 - 18:20.
pharmaphorum
NOVEMBER 20, 2022
Elizabeth Holmes, the founder and former chief executive of blood testing biotech Theranos, has been sentenced after being convicted of defrauding investors in the company earlier this year, receiving a prison sentence of more than 11 years in a California court. That’s shorter than the 15 years sought by prosecutors, but considerably longer than the 18 months’ house arrest that Holmes’ defense attorneys had pushed for, and there is likely to be an appeal against the sentence,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Store News
NOVEMBER 20, 2022
CVS Health is investing $6.2 million to build 36 new affordable housing units in Bel Aire, Kan., and $14.3 million to build 120 affordable housing units in Seattle, Wash.
pharmaphorum
NOVEMBER 20, 2022
The COVID-19 pandemic stopped the world in its tracks. It provided a range of new challenges for industry stakeholders, including governments, public health bodies, and regulatory agencies – to name a few. In addition, it offered the opportunity for new solutions and approaches to many of today’s healthcare challenges. The world responded to the crisis at unprecedented speed, as leaders and experts focused on different ways to operate and succeed within the constraints of a new dynamic.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Store News
NOVEMBER 20, 2022
These days, many U.S. consumers also want a little something extra in the name of health and wellness.
Fierce Healthcare
NOVEMBER 20, 2022
Kaiser Permanente averts strike as nurses win 22.5% pay hike in new deal. hlandi. Sun, 11/20/2022 - 14:24.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 20, 2022
Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease. The latest development was based on findings from a Phase II clinical trial of the vaccine in South Africa as well as from the Phase III Prevent-19 trial in the US and Mexico.
pharmaphorum
NOVEMBER 20, 2022
Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up. In its third-quarter results update , the Tuebingen, Germany-based biotech said it had been informed by GSK in early October that it would be terminating their partnership announced in February 2020, adding that the decision was made “unrelated to the programmes and the progress achieved in the collaboration to date.” The de
PharmExec
NOVEMBER 20, 2022
Webinar Date/Time: Thu, Dec 8, 2022 2:00 PM EST.
Hospital Pharmacy Europe
NOVEMBER 20, 2022
Dupixent (dupilumab) has been recommended for EU approval as the first available treatment for patients with prurigo nodularis. According to a press release by the manufacturer, Sanofi, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the EU to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Med Ed 101
NOVEMBER 20, 2022
We’ve been doing some work lately to develop a chart of commonly used drugs with pharmacogenomic considerations. In anticipation of that table, I thought I’d share my top 5 medications that have pharmacogenomic considerations. If you are taking a board exam (BCMTMS, NAPLEX, BCACP, BCPS, or BCGP) soon, I would definitely pay a little closer […].
Hospital Pharmacy Europe
NOVEMBER 20, 2022
Anticoagulation reversal agents used for intracranial haemorrhage have similar levels of efficacy and safety according to a systematic review. The use of different anticoagulant reversal agents after an intracranial haemorrhage, provides a similar level of efficacy and safety according to the findings of a meta-analysis by US researchers. The direct oral anticoagulants (DOACs) are increasingly preferred over warfarin in DOAC-eligible patients with atrial fibrillation and patients with venous thr
BioPharm
NOVEMBER 20, 2022
Webinar Date/Time: Wed, Dec 14, 2022 11:00 AM EST.
Pharmaceutical Technology
NOVEMBER 20, 2022
The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioPharm
NOVEMBER 20, 2022
Webinar Date/Time: Tue, Dec 6, 2022 11:00 AM EST.
BioPharm
NOVEMBER 20, 2022
This Application Note presents streamlined workflows for preparation of InstantPC and 2-AB labeled N-glycans coupled with analysis using Agilent LC/FLD/MS.
Expert insights. Personalized for you.
122 
Let's personalize your content